Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
The major indexes fell and AI stocks dived through midweek, partly on soaring oil and yields, but Microsoft and Amazon provided support.
IDCC beat Q2 estimates, raised 2026 revenue guidance and posted record recurring revenue, but investors still face valuation and licensing-related risks.
(Bloomberg) -- Apnimed Inc., a late-stage drug developer focused on sleep apnea rose 6.3% on Friday after raising $192 million in an upsized US initial public offering.Most Read from BloombergSingapore's Gated Island for the Rich Is Marred by Decayed HomesAnthropic AI Models Hacked Three Organizations During TestsMicrosoft’s $450 Billion Jump Is Biggest in Stock Market HistoryChip Stocks Post Biggest Advance Since April 2025: Markets WrapUS Strikes Iran Again as Conflict Spreads Across Middle Ea
CLB's Q2 earnings top estimates despite lower revenues and profit as Production Enhancement strength offsets Reservoir Description weakness.
IES Holdings shot up 31% on Friday after giving a strong outlook for AI data centers. Big Tech names Microsoft and Amazon also soared.
Merit Medical's Q2 adjusted EPS jumps 18% as revenues rise 9.5%, margins expand and 2026 guidance increases after broad product growth.
Revenue of $16.99 billion and adjusted EPS of $3.65 both beat estimates
Investing.com -- A $21 billion U.S. Air Force program managed by Boeing Co. to modernize the B-52 bomber fleet is facing cost increases and schedule delays during its early development phase, according to a Government Accountability Office report released Friday.
Energy titans ExxonMobil (XOM) and Chevron (CVX) both released second quarter earnings results ahead of Friday's market open. Morning Brief Host Julie Hyman is joined by Yahoo Finance Breaking News Reporter Jake Conley and Trustless Media Founder Zack Guzman to help assess both companies' production outlook and how they are managing debt.
RBC Bearings (RBC) delivered earnings and revenue surprises of +13.45% and +2.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Thursday night earnings split two of the biggest names in tech in completely opposite directions, and the reason behind the gap reveals exactly where the AI infrastructure boom is creating winners and where it is quietly crushing margins.
AbbVie (ABBV) delivered earnings and revenue surprises of +0.28% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Dominion Energy (D) delivered earnings and revenue surprises of +8.22% and +10.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
The electrical infrastructure supplier reported second-quarter earnings per share of $3.15, with sales of $8.5 billion. Wall Street was looking for EPS of $3.07 and sales of $8.2 billion.
AbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.
The IPO market has made an impressive comeback this year. Momentum began building in the first quarter and accelerated in the second, with traditional IPOs raising $114.1 billion through June 30, 2026 – roughly seven times the amount raised during the first half of 2025. SpaceX, the largest IPO in Wall Street history, understandably dominated the headlines and made Elon Musk the world’s first trillionaire, but the strength of the market extended well beyond a single blockbuster listing.Claim 55%
AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.
Robinhood Markets (Nasdaq: HOOD) reported its earnings for the second quarter of 2026 on July 29. The brokerage platform, popular for its equity, crypto, and tokenized stock offerings, generated $1.31 billion in revenue and $0.62 in earnings per share (EPS), beating Wall ...
The e-commerce and cloud giant topped second quarter expectations as accelerating cloud growth at Amazon Web Services (AWS) helped drive strong results.
The e-commerce and cloud giant topped second quarter expectations as accelerating cloud growth at Amazon Web Services (AWS) helped drive strong results.
Moderna (MRNA) delivered earnings and revenue surprises of 0.00% and +14.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stock Market Today: The Dow Jones index rises Friday even as Apple dives on a weak sales forecast. Amazon stock surges on earnings.
Investing.com -- Colgate-Palmolive Company (NYSE:CL) reported second-quarter earnings before the open on Friday, topping earnings expectations.
Moderna posted a narrower per-share loss and higher revenue in its latest quarter, but shares were tumbling anyway. Moderna posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year. The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.
Chevron (CVX) delivered earnings and revenue surprises of +4.48% and +21.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
July 31 (Reuters) - Enbridge beat estimates for second-quarter adjusted profit on Friday, helped by higher volumes of liquids transported on its Mainline system.
Private-fund manager Ares Management reported record fundraising of $36.4 billion in the second quarter, rebounding from a slowdown earlier in the year. The amount of money raised climbed about 24% from the first quarter of this year and 39% from the second quarter of 2025. Fundraising from Ares business development companies—a type of private-credit fund commonly sold to individual investors—dipped, but that was offset by a surge in sales of funds to institutional clients, like pensions and sovereign wealth funds.
Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 2.1% year on year to $145 million. Its GAAP loss of $1.97 per share was 4.2% above analysts’ consensus estimates.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
